Quigley Harry A
Glaucoma Center of Excellence, Wilmer Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Prog Brain Res. 2015;220:59-86. doi: 10.1016/bs.pbr.2015.04.003. Epub 2015 Jul 2.
Glaucoma, the second most common cause of world blindness, results from loss of retinal ganglion cells (RGC). RGC die as a consequence of injury to their axons, as they pass through the transition between the environment within the eye and that of the retrobulbar optic nerve, as they course to central visual centers. At the optic nerve head (ONH), axonal transport becomes abnormal, at least in part due to the effect of strain induced by intraocular pressure (IOP) on the sclera and ONH. Animal glaucoma models provide the ability to study how alterations in ocular connective tissues affect this pathological process. New therapeutic interventions are being investigated to mitigate glaucoma blindness by modifying the remodeling of ocular tissues in glaucoma. Some genetically altered mice are resistant to glaucoma damage, while treatment of the sclera with cross-linking agents makes experimental mouse glaucoma damage worse. Inhibition of transforming growth factor β activity is strikingly protective. Treatments that alter the response of ocular connective tissues to IOP may be effective in protecting those with glaucoma from vision loss.
青光眼是全球第二大致盲原因,是由视网膜神经节细胞(RGC)丧失所致。当RGC的轴突穿过眼球内部环境与球后视神经环境之间的过渡区域并向中枢视觉中枢传导时,会因轴突损伤而死亡。在视神经乳头(ONH)处,轴突运输变得异常,至少部分原因是眼内压(IOP)对巩膜和ONH施加的应变作用。动物青光眼模型使我们有能力研究眼内结缔组织的改变如何影响这一病理过程。目前正在研究新的治疗干预措施,通过改变青光眼患者眼组织的重塑来减轻青光眼致盲。一些基因改造小鼠对青光眼损伤具有抗性,而用交联剂处理巩膜会使实验性小鼠青光眼损伤加重。抑制转化生长因子β活性具有显著的保护作用。改变眼内结缔组织对IOP反应的治疗方法可能对保护青光眼患者避免视力丧失有效。